This study aims to determine analgesic and anti-inflammatory effects of dual-wavelength PBM in people with symptomatic knee OA.
Clinically confirmed knee osteoarthritis (OA) based on the American College of Rheumatology (ACR) criteria with symptomatic pain for ≥ 3 months
Average knee-pain intensity ≥ 30/100 on both the Daily Symptom Diary (DSD) run-in and CATI
Age ≥ 50 years
Ability to give informed consent, attend visits, and complete ≥ 4 of 7 DSD entries pre-randomization
Active systemic rheumatic condition (e.g., rheumatoid arthritis, systemic lupus erythematosus)
Fibromyalgia with pain outside the knee that is equal to or worse than knee pain
Clinically significant surgery on the index knee (e.g., arthroplasty, osteotomy)
Knee surgery within the past 6 weeks